Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
26 August 2024 |
Main ID: |
NCT00815906 |
Date of registration:
|
18/12/2008 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis
|
Scientific title:
|
An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of SBI-087 Administered To Japanese Subjects With Rheumatoid Arthritis |
Date of first enrolment:
|
December 2008 |
Target sample size:
|
20 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/ct2/show/NCT00815906 |
Study type:
|
Interventional |
Study design:
|
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
Phase:
|
Phase 1
|
|
Countries of recruitment
|
Japan
| | | | | | | |
Contacts
|
Name:
|
Pfizer CT.gov Call Center |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Pfizer |
| | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Must meet American College of Rheumatology criteria for rheumatoid arthritis with
functional class I to III.
- Rheumatoid arthritis disease onset at >16 years of age and duration of disease at
least 6 months.
- Men or women of nonchildbearing potential (WONCBP), aged 20 to 70 years, inclusive
at the screening visit.
Exclusion Criteria:
- Any significant health problems other than rheumatoid arthritis.
- Treatment of greater than 10 mg of prednisone per day.
- Therapy with immunosuppressants within 6 months before study day 1
Age minimum:
20 Years
Age maximum:
70 Years
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
Arthritis, Rheumatoid
|
Intervention(s)
|
Drug: SBI-087
|
Primary Outcome(s)
|
Safety and tolerability as determined by the number and severity of adverse events at the different dose levels
[Time Frame: 12 months]
|
Secondary Outcome(s)
|
To investigate if changes in biomarkers (eg, complement activation markers, B-cells, CRP, IgE and tryptase levels) are related to the occurrence of systemic reactions on the day of infusion or injection of SBI-087
[Time Frame: 12 month]
|
To describe the single-dose PK and PD profiles (B-cell count) after a SBI-087 administration in subjects with RA
[Time Frame: 12 months]
|
To evaluate the effect of a pretreatment regimen on the occurrence of systemic reactions following SC administration of 100 mg or 200 mg SBI-087
[Time Frame: 12 month]
|
Secondary ID(s)
|
3227K1-1001
|
B2261002
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|